|
Match
|
Document |
Document Title |
|
|
US20090286800 |
Glucokinase Activators
Compounds are provided for use with glucokinase that comprise the formula:
wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of...
|
|
|
US20090286772 |
2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles
The invention encompasses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme...
|
|
|
US20090281118 |
Selective Ligands for the Neuronal Nicotinic Receptors and Uses Thereof
The present application describes selective ligands of formula (I)
for neuronal nicotinic receptors (NNRs), more specifically for the α4β2 NNR subtype, compositions thereof, and methods of...
|
|
|
US20090281088 |
BICYCLIC NITROIMIDAZOLE-SUBSTITUTED PHENYL OXAZOLIDINONES
The current invention provides a series of bicyclic nitroimidazole-substituted phenyl oxazolidinones in which a bicyclic nitroimidazole pharmacophore is covalently bonded to a phenyl oxazolidinone,...
|
|
|
US20090280175 |
Multilayer Proton Pump Inhibitor Tablets
Multilayer tablets of a proton pump inhibitor essentially bioequivalent in terms of plasma C max and AUC to capsules and/or tablets consisting of multiple unit pellets of the proton pump inhibitor...
|
|
|
US20090280173 |
Multilayer Omeprazole Tablets
Multilayer tablets of Omeprazole and/or a salt thereof essentially bioequivalent in terms of plasma Omeprazole C max and AUC to Omeprazole capsules and/or Omeprazole Magnesium tablets consisting...
|
|
|
US20090275572 |
FAB I INHIBITORS
Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.
|
|
|
US20090274756 |
Stabilized composition
It is intended to provide a pharmaceutical composition which contains a proton pump inhibitor and is stable even if it is stored for a long time. It is also intended to provide a pharmaceutical...
|
|
|
US20090274755 |
Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
The present invention is directed to a process for the catalytic oxidation of the thioether 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)meth
ylthio)-1H-benzimidazole to its sulfoxide:...
|
|
|
US20090274650 |
INHIBITORS OF ASPARTYL PROTEASE
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors...
|
|
|
US20090274632 |
Identification of human T2R receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in composition and use thereof
The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds present in, e.g., coffee. Also, the...
|
|
|
US20090270457 |
6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which exhibit antibacterial properties. The present invention further...
|
|
|
US20090270407 |
FUNGICIDAL ISOXAZOLIDINES
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof,
wherein
A, B, D, R 1 , R 2 , R 3 , X and m are as defined in the disclosure....
|
|
|
US20090270372 |
NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS
A subject of the present Application is novel derivatives of benzimidazole and imidazopyridine which have a good affinity for certain sub-types of melanocortin receptors, in particular the MC4...
|
|
|
US20090270332 |
GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF
The present invention is based on the discovery of genetic polymorphisms that are associated with venous thrombosis. In particular, the present invention relates to nucleic acid molecules...
|
|
|
US20090264473 |
Novel Crystalline Forms of Antidiabetic Compounds
A novel crystalline anhydrate of the free acid and a crystalline anhydrous besylate salt of a selective PPAR gamma partial agonist which has a fused bicyclic aromatic group attached to an...
|
|
|
US20090264468 |
Methods for treating a disease in which Rho kinase is involved
A method for treating a disease in which Rho kinase is involved. The method is carried out by administering to a patient in need thereof a pharmaceutically effective amount of a compound of the...
|
|
|
US20090264405 |
Cetp Inhibitors
Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or...
|
|
|
US20090264385 |
STABILIZED COMPOSITIONS CONTAINING ALKALINE LABILE DRUGS
A stabilized bioadhesive composition containing an alkaline labile drug and a method for its preparation are provided. In one aspect, the composition is a hot-melt extruded (HME) composition...
|
|
|
US20090263475 |
DEXLANSOPRAZOLE COMPOSITIONS
Premixes of dexlansoprazole with pharmaceutical excipients, processes for preparing premixes, pharmaceutical formulations containing the premixes, and their use in treatment of erosive esophagitis...
|
|
|
US20090258909 |
Novel Benzimidazole Derivatives Useful as Selective Androgen Receptor Modulators (SARMS)
The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the...
|
|
|
US20090258908 |
Crystalline S-Omeprazole Strontium Hydrate, Method For Preparing Same, And Pharmaceutical Composition Containing Same
This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility...
|
|
|
US20090258907 |
COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES
Disclosed herein are compounds of formula (I) or pharmaceutical acceptable salts thereof,
wherein X, R 1 , R 2 , R 3 , R 4 , L 1 , and m, are defined in the specification. Compositions...
|
|
|
US20090258884 |
Substituted amides
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases...
|
|
|
US20090253750 |
3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES
The present invention provides 3-indazoyl-4-pyridylisothiazoles or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods of using the same, as well as...
|
|
|
US20090253697 |
Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors
The disclosure relates to compounds of formula (I):
wherein R1, R2, and R3 are as defined in the disclosure, compositions comprising said compounds, methods for their preparation, intermediates...
|
|
|
US20090253684 |
LEUKOTRIENE B4 INHIBITORS
Provided herein are compounds of the formula (I):
as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and...
|
|
|
US20090247508 |
Benzoimidazole Compounds
Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H 4 receptor, and in treating conditions such as inflammation, H 4 ...
|
|
|
US20090246137 |
PYRIDYL DERIVATIVES AS CFTR MODULATORS
The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”),...
|
|
|
US20090233970 |
COMBINED NSAID AND ACID BLOCKER FORMULATION AND METHOD
The present invention is directed to co-administration of a non-steroidal anti-inflammatory agent (NSAID) and acid blocking agent for the treatment of pain and inflammation with reduced...
|
|
|
US20090227633 |
Methods to inhibit tumor cell growth by using proton pump inhibitors
Methods of treating one or more growth deregulated cells are disclosed. An effective amount of a pharmaceutical composition including a proton pump inhibitor is administered thereby treating a...
|
|
|
US20090227592 |
COMPOUNDS EFFECTING GLUCOKINASE
The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R 1 , R 2 , R 3 , n and m are as described in the specification, in the preparation of a...
|
|
|
US20090227555 |
Novel Pyridine Compounds
The present invention relates to certain novel pyridin compounds of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc,...
|
|
|
US20090226511 |
NOVEL PHARMACEUTICAL FORMULATION IN THE FORM OF CELLULOSE CAPSULES SUITABLE FOR BENZIMIDAZOLE DERIVATIVES
A filled cellulose capsule for oral administration, wherein the capsule comprises a cellulose derivative as the base and the filling comprises a therapeutically effective amount of a benzimidazole...
|
|
|
US20090221646 |
CRYSTALLINE SOLVATE OF OMEPRAZOLE SODIUM
The present invention belongs to the field of pharmaceutical industry and relates to novel crystalline omeprazole sodium ethanol solvate and to the process for its preparation, which acts as...
|
|
|
US20090221645 |
Dihydroimidazothiazole Derivatives
Compounds of formula (I) or pharmaceutically acceptable salts thereof, exhibit 5-HT 1A agonism in addition to noradrenaline reuptake inhibition and optionally also 5-HT reuptake inhibition are...
|
|
|
US20090221587 |
NOVEL INSECTICIDES
Compounds of formula (I), wherein the substituents are as defined in claim ( 1 ), and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula (I)...
|
|
|
US20090220591 |
Pharmaceutical Compositions Comprising Non-Steroidal Antiinflammatory Drug, Antipyretic-Analgesic Drug and Proton Pump Inhibotor
The present invention relates to pharmaceutical compositions in the form of fixed combination comprising non-steroidal anti-inflammatory drug or its single enantiomers or salts thereof,...
|
|
|
US20090220552 |
FORMULATIONS CONTAINING PANTOPRAZOLE FREE ACID AND ITS SALTS
The invention relates to new formulations and dosage units of solid crystalline pantoprazole free acid and its salts (e.g., pantoprazole sodium sesquihydrate) that are resistant to gastric juice...
|
|
|
US20090215831 |
INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES
Chemical syntheses and medical uses of novel inhibitors of the gastric H + , K + -ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by...
|
|
|
US20090215830 |
Multiple ppi dosage form
Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an...
|
|
|
US20090215753 |
Topical Compositions for Paediatric Use
The present invention provides pharmaceutical compositions for treating a paediatric mammal, the compositions comprising a therapeutic agent and a pharmaceutically acceptable carrier, the...
|
|
|
US20090214602 |
ORAL DOSAGE FORMS INCLUDING AN ANTIPLATELET AGENT AND AN ENTERICALLY COATED ACID INHIBITOR
The present disclosure provides oral dosage forms comprising an antiplatelet agent and an enterically coated acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and...
|
|
|
US20090214599 |
PROTON PUMP INHIBITOR FORMULATIONS, AND METHODS OF PREPARING AND USING SUCH FORMULATIONS
Pharmaceutical formulation comprising at least one proton pump inhibitor structured and arranged to provide an initial pH-dependent delayed release, and a pH-dependent extended release of the at...
|
|
|
US20090209593 |
NOVEL ANTIBACTERIAL AGENTS
This invention relates to novel macrolides, to the preparation of novel macrolides, to the use of such novel macrolides for preventing, treating, or ameliorating various conditions, and to the use...
|
|
|
US20090209592 |
INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES
Chemical syntheses and medical uses of novel inhibitors of the gastric H + , K + -ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by...
|
|
|
US20090209591 |
Pharmaceutical product for injection
The present invention is related to a pharmaceutical product for injection comprising a container including a closure suitable for preparations for injection, the container containing an acid...
|
|
|
US20090209571 |
Phenanthrene derivatives as MPGES-1 inhibitors
The invention encompasses novel compounds of Formula or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and...
|
|
|
US20090209547 |
C-8 HALOGENATED MACROLIDES
The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which exhibit antibacterial properties. The present invention further...
|
|
|
US20090209540 |
Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same
Disclosed are biaryl benzoimidazole derivatives. They have an inhibitory effect on calcium influx in HEK cells, thereby showing a powerful antagonistic effect on a vanilloid receptor, and further...
|